EUROAPI Hungary Ltd.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Lessors of Real Property, Not Elsewhere Classified, Land Subdividers and Developers, Except Cemeteries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about EUROAPI Hungary Ltd.
Live alerts from global media, monitored by Business Radar
2025-03-31 (boursier.com)
Euroapi: new pressure stroke
(Boursier.com) - Euroapi Reperd 5.6% at 2.70 euros this Monday, while Bernstein degraded the 'outperformance' file to 'market performance' with a target price adjusted from 4.40 to 2.90 euros. The specialist in pharmaceutical active ingredients recently reported a 2024 negative operating profit to -120.4 ME (-234.3 euros in 2023) for a turnover of 911.9 million euros, down -10% and -9.4% at constant exchange rates (TCC). By excluding the Brindisi site, assigned by a temporary production suspension, the turnover would have fallen by -7.3%. The gross margin was established at 142.4 ME (164.6 ME in 2023). The net loss amounts to -130.6 me. The company ended the year 2024 with a net cash position of 25.2 ME, against a net debt of -171 ME at the end of December 2023.
Read more
2024-10-15 (globenewswire.com)
EUROAPI closes the financing of its FOCUS-27 plan
Press Release Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply...
Read more